Browse the evidence

GLP-1 receptor agonists (semaglutide) significantly improve quality of life and exercise capacity in obese patients with heart failure with preserved ejection fraction (HFpEF), primarily through substantial weight loss.

For obese patients with HFpEF, GLP-1 agonists like semaglutide are effective at improving quality of life and exercise capacity, largely by driving significant weight loss (approx. 13%). While these drugs are promising, their benefits appear closely tied to weight reduction rather than unique cardiac mechanisms. Therefore, they should be viewed as one option among others, including caloric restriction and supervised exercise, which may offer similar benefits at a lower long-term cost.

Once-weekly semaglutide (0.5 mg and 1.0 mg) as an add-on to metformin significantly improves glycemic control (HbA1c), reduces body weight, and lowers blood pressure compared to once-daily sitagliptin in patients with type 2 diabetes.

For patients with Type 2 Diabetes on metformin who need better blood sugar and weight control, switching to once-weekly semaglutide is more effective than switching to the oral drug sitagliptin. Semaglutide lowers HbA1c, weight, and blood pressure more significantly. However, be aware that semaglutide carries a higher risk of side effects and treatment discontinuation compared to sitagliptin.

Urban design that promotes physical activity and provides green space reduces cardiovascular mortality and risk factors, whereas urban environments that hinder activity and lack green space increase risk.

Prioritize living in or visiting areas with significant tree canopy and green space. If you live in a dense urban area, seek out parks and green corridors. These spaces not only encourage physical activity but also mitigate heat stress and air pollution, directly lowering cardiovascular risk.

Achieved weight loss, rather than dietary protein quantity or red meat inclusion, is the primary driver of improved glucose control and body composition in adults with type 2 diabetes.

If you have Type 2 Diabetes, focus on losing weight rather than obsessing over whether your protein intake is 'high' or if you eat beef. This study shows that losing weight improves your blood sugar and body composition regardless of whether you eat a high-protein diet with beef or a normal-protein diet without it. Choose a dietary pattern you can stick to that creates a calorie deficit, and the health benefits will follow.

Once-weekly subcutaneous semaglutide 2.4 mg significantly improves weight-related quality of life (WRQOL) and health-related quality of life (HRQOL) in East Asian adults with overweight or obesity, specifically enhancing physical functioning, psychosocial well-being, and total quality of life scores compared to placebo.

If you are an East Asian adult with overweight or obesity, once-weekly semaglutide 2.4 mg, combined with a modest 500-kcal daily calorie deficit and 150 minutes of weekly physical activity, has been shown to significantly improve your physical functioning, psychosocial well-being, and overall quality of life compared to placebo. This treatment helps you feel better in social situations and perform daily activities more comfortably.

Vitamin E supplementation (800 IU daily) improves steatohepatitis, hepatic steatosis, and inflammation in adults with MASH who do not have diabetes, but does not improve fibrosis.

If you have MASH and do not have diabetes, your doctor may recommend 800 IU of Vitamin E daily. This dose has been shown to reduce liver inflammation and fat over 96 weeks, though it does not reverse scarring (fibrosis).

Discontinuation of GLP-1 receptor agonists leads to significant weight regain (approx. two-thirds of lost weight) and loss of cardiometabolic benefits, driven partly by a surge in ghrelin.

If you stop taking GLP-1 medications, you will likely regain most of the weight you lost. This is a physiological response (ghrelin surge), not a failure of willpower. To maintain weight loss, you must either stay on the medication indefinitely or switch to a more durable intervention like surgery.

Tirzepatide treatment produces similar improvements in glycemic control (HbA1c) and body weight in patients with early-onset type 2 diabetes (diagnosed before age 40) compared to those with later-onset type 2 diabetes.

If you were diagnosed with type 2 diabetes before age 40, you may have heard that your condition is harder to treat. This analysis of major clinical trials shows that the medication tirzepatide works just as well for you as it does for older patients, significantly lowering blood sugar and body weight. You should discuss this option with your doctor, as it addresses the specific metabolic challenges often seen in early-onset diabetes.

Performing leg extension exercises with a reduced hip flexion angle (approx. 40°) produces significantly greater hypertrophy in the rectus femoris compared to a standard upright hip angle (90°), while having no differential effect on the vastus lateralis.

If your goal is to maximize growth in the rectus femoris (the muscle in the middle of your thigh), adjust your leg extension machine to lean back slightly (approx. 40 degrees of hip flexion) rather than sitting fully upright. This position likely places the rectus femoris at a more optimal length for growth. Note that this change does not appear to affect the vastus lateralis (outer thigh) growth, so both positions are valid for general quad development.

Significant initial weight loss (decrease in BMI) is a strong predictor of high adherence to liraglutide treatment.

If you experience significant weight loss in the first few months of liraglutide treatment, you are much more likely to stick with the medication long-term. This positive feedback loop is a key factor in maintaining adherence.

Higher socioeconomic status and non-smoking status are significantly associated with higher adherence to liraglutide treatment.

Patients with higher income/education levels and those who do not smoke are more likely to adhere to their liraglutide prescription. Addressing financial barriers and supporting smoking cessation may improve adherence rates.

Semaglutide 2.4 mg weekly reduces all-cause mortality and major adverse cardiovascular events in overweight/obese patients with preexisting cardiovascular disease but no diabetes, yet remains cost-ineffective at current pricing relative to standard care.

For a patient with heart disease and obesity but no diabetes: Semaglutide 2.4mg weekly significantly lowers your risk of heart attack, stroke, and death compared to standard care. However, because the drug is expensive, public health systems may not cover it unless the price drops. You should discuss the clinical benefits with your doctor, but be aware that insurance coverage might be denied or require prior authorization due to cost-effectiveness thresholds.

Long-term use of FDA-approved antiobesity medications (AOMs) for at least 112 days is associated with a statistically significant reduction in total health care costs and non-AOM medication costs by the second year of treatment compared to no treatment.

If you have obesity and are considering FDA-approved weight loss medications, discuss long-term coverage with your insurer. While the medication itself costs money, studies show that maintaining use for at least 112 days (approx. 4 months) can lead to significant reductions in other medical bills (like prescriptions for diabetes or blood pressure) by the second year, potentially saving money overall compared to not treating the obesity.

GIPR agonism mitigates the gastrointestinal adverse effects (nausea/vomiting) associated with GLP-1R agonism, thereby allowing for higher maximal tolerated doses of GLP-1-based therapies.

If you are struggling with nausea on a GLP-1 drug, switching to a combination GIP/GLP-1 drug might allow you to take a higher dose without more side effects. The GIP component helps cancel out the nausea caused by the GLP-1 component.

Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrates superior kidney and cardiovascular benefits compared to GLP-1 RAs alone, including significant reductions in albuminuria and eGFR decline.

Tirzepatide (Mounjaro/Zepbound) is a newer option that targets both GLP-1 and GIP hormones. It may offer better kidney and heart protection than older GLP-1 drugs. Discuss with your doctor if you have kidney disease, as it can slow kidney function decline significantly. It is also highly effective for weight loss.

Combining a low-carbohydrate diet (approx. 50g carbs/day) with exercise (MICT or HIIT) significantly reduces anxiety levels in overweight young women, whereas the low-carbohydrate diet alone does not.

If you are overweight and feeling anxious, simply cutting carbs may not help your mental health and might even cause social stress. However, adding regular exercise (either moderate continuous cycling or high-intensity intervals) to a low-carb diet significantly reduces anxiety. Focus on the exercise component as the key driver for mental health benefits, not just the diet.

Adding exercise to a low-carbohydrate diet improves cardiorespiratory fitness (VO2peak) and reduces systolic blood pressure, but does not provide additional weight loss benefits compared to the low-carbohydrate diet alone.

If you are doing a low-carb diet, adding exercise won't necessarily make you lose weight faster than the diet alone. However, it will significantly improve your heart health, blood pressure, and mental well-being. Do exercise for these health benefits, not just for extra weight loss.

The brain utilizes two distinct, opponent neural networks to process food cues: a Limbic network that automatically encodes hedonic value (pleasantness/appetite), and a Prefrontal network that encodes regulatory information (healthfulness, processing level, and self-control requirements).

When you see food, your brain automatically splits the information: one part tells you how good it tastes (Limbic), and another tells you how processed/healthy it is (Prefrontal). To make better choices, consciously engage the Prefrontal network by focusing on the food's processing level or health attributes, rather than just fighting the taste. This leverages the brain's natural regulatory architecture.

GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss, leading to improved physical functioning, daily living capacity, and mental well-being, despite common gastrointestinal side effects.

GLP-1RAs are effective for weight loss and improving daily functioning. Expect gastrointestinal side effects like nausea, which often subside after a few weeks. The benefits of weight loss and improved mobility often motivate patients to persist despite these side effects.

Female patients report greater benefits from GLP-1RA treatment compared to male patients, particularly in mental well-being and physical functioning.

Be aware that female patients may report greater improvements in quality of life and mental well-being from GLP-1RAs than male patients. This is a documented trend in patient experiences.

GLP-1RAs improve the management of sweet cravings and reduce emotional eating.

GLP-1RAs can help reduce sweet cravings and emotional eating, making it easier to maintain weight loss. This is a reported benefit by patients.

Acute exercise triggers the release of 'exerkines' (such as IL-6, BNP, and FGF21) from various tissues, which act as systemic signals to coordinate energy mobilization, metabolic adaptation, and cross-tissue communication.

Understand that your muscles and organs 'talk' to each other during exercise through chemical signals called exerkines. This is why exercise benefits not just the muscles working, but also your heart, brain, and metabolism. Consistent exercise ensures these beneficial signals are regularly released.

NuSH therapies induce significant weight loss that often includes loss of lean mass and skeletal muscle, creating a risk for sarcopenic obesity if body composition is not monitored.

Monitor your body composition, not just your weight. If you are on NuSHs, ensure your treatment plan includes resistance training and protein optimization to preserve muscle mass, as weight loss alone may hide muscle loss.

The semaglutide 2.4 mg single-dose pen-injector (SPI) demonstrates high ease-of-use and acceptability, with the vast majority of participants finding it easy to use and training, and preferring it over daily oral medication.

If you are considering semaglutide 2.4 mg via the single-dose pen, expect it to be easy to use. Most users found the training simple and the injection process easy. While some initial use errors (like seeing liquid on the skin) can occur, they are common in the first few injections and tend to disappear with practice. The device is generally preferred over daily pills due to its weekly frequency and ease of use.